Helsinn Healthcare S.A. et al. v. GAVIS Pharma LLC

I'll research this case through web searches to build an accurate overview.

Case Overview: Helsinn Healthcare S.A. v. Gavis Pharma LLC, No. 3:15-cv-01228 (D.N.J.)

Parties. Both plaintiffs are brand-side pharmaceutical companies, not NPEs. Helsinn Healthcare S.A. is a privately held Swiss pharma group headquartered in Lugano-Pazzallo that holds NDA No. 021372 for ALOXI® (palonosetron hydrochloride) injection, the first-in-class 5-HT₃ receptor antagonist used to prevent chemotherapy-induced and post-operative nausea and vomiting. Roche Palo Alto LLC — a Delaware entity whose corporate parent is Roche Holding Ltd., and successor to the Roche/Syntex 5-HT₃ program from which palonosetron was in-licensed by Helsinn — is a co-plaintiff and, per the face of the patent and FDA's Orange Book listing, a co-assignee of the asserted patent. The defendant, Gavis Pharma LLC, was a privately held Somerset, New Jersey generics company (affiliated with Novel Laboratories) specializing in niche dosage forms, with roughly 250 New Jersey employees, 66 pending ANDAs and, by its own accounting, 25 Paragraph IV filings. Notably, Gavis was acquired by Mumbai-based Lupin Limited for $880 million — announced July 23, 2015 and closed March 9, 2016 — meaning Lupin inherited this litigation (and its resolution) as part of its first U.S. manufacturing footprint. See Lupin press release, July 23, 2015 (lupin.com/media/press-releases/lupin-acquires-gavis-to-expand-us-generic-business); FiercePharma, Mar. 9, 2016.

Accused product and patent. This is a classic Hatch-Waxman § 271(e)(2) ANDA case. Helsinn and Roche sued over Gavis's abbreviated new drug application seeking approval to market generic palonosetron hydrochloride injection, 0.25 mg/5 mL and 0.075 mg/1.5 mL single-use vials, before expiration of the Orange Book-listed patents. The sole patent identified in the case metadata, U.S. Patent No. 7,947,724 ("Liquid pharmaceutical formulations of palonosetron"), issued May 24, 2011 to inventors Calderari, Bonadeo, Cannella and the Braglias, claims priority to January 30, 2003, and is co-assigned to Helsinn and Roche Palo Alto. In one line: it claims shelf-stable aqueous liquid (injectable/oral) palonosetron hydrochloride formulations — the formulation-of-matter patents Helsinn used to convert an off-patent-turning molecule into a long-life Orange Book estate (the '724 and its siblings were listed as expiring July 30, 2024 with pediatric exclusivity, per FDA ANDA approval letters for Teva and Dr. Reddy's). I could not verify from accessible sources the specific claims asserted against Gavis or Gavis's ANDA number; in the parallel consolidated case against Teva, Dr. Reddy's and Sandoz, Helsinn asserted claims 2 and 9 of the '724 (see Final Judgment, Helsinn v. Teva, No. 11-3962 (MLC)(DEA), D.I. 361, Nov. 16, 2015).

Posture, venue, and significance. Filed February 13, 2015 in the District of New Jersey and assigned to Judge Mary L. Cooper with Magistrate Judge Douglas E. Arpert — the same judge who presided over Helsinn's consolidated ALOXI litigation (Helsinn v. Dr. Reddy's/Teva/Sandoz, No. 11-3962) — the case was never litigated on the merits. Gavis waived service on March 12, 2015 (D.E. 8), obtained extensions to answer (D.E. 13), and the parties submitted a proposed Consent Judgment and Dismissal Order, signed by Judge Cooper on August 25, 2015 (D.E. 15) — roughly six months from filing and, notably, one month after Lupin's acquisition announcement. The specific terms of that consent judgment (licensed entry date, admissions, injunction scope) are not disclosed in the sources I could access; the docket shows no answer, no claim construction, and no discovery activity. Venue mattered both because Gavis was physically present in New Jersey (Somerset) and because D.N.J. was the established home of Helsinn's coordinated ALOXI docket, with Saul Ewing (Newark) and Paul Hastings for Helsinn and Loeb & Loeb for Roche.

The case is notable mainly for what it sits inside: it was one of at least fifteen ANDA suits Helsinn filed to defend the ALOXI franchise (a fact recited in Sagent's 2018 motion to enforce, Helsinn v. Sagent, No. 16-173 (SRC)(CLW), D.I. 53). And the '724 patent became the vehicle for the most consequential patent case in recent pharma history: after Judge Cooper held the '724 (with the '725 and '424) valid and infringed following a June–August 2015 bench trial, the Federal Circuit reversed in Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., 855 F.3d 1356 (Fed. Cir. 2017), and the Supreme Court unanimously affirmed on January 22, 2019, holding that a pre-AIA-style "secret sale" — Helsinn's 2001 supply-and-purchase agreement with MGI Pharma, disclosed only in redacted form in an 8-K — triggers the AIA on-sale bar under 35 U.S.C. § 102(a)(1). That ruling gutted the '724 estate: Teva launched generic ALOXI at risk on March 23, 2018, followed by Dr. Reddy's and Sandoz, and the ALOXI exclusivity wall that Gavis bought peace against in 2015 was gone within three years. For NPE/PAE-watchers, the case is instead a useful counter-example: an operating-company plaintiff using a thick formulation-patent estate and rapid consent judgments — not damages trials — to sequence generic entry dates, with the entire strategy ultimately unwound by a single prior commercial agreement.

Sourcing caveats: Party names, patent, judges, filing date and the D.E. 15 consent judgment are corroborated by the docket summary (unicourt.com record for 3:15-cv-01228) and cross-referenced to the related D.N.J. filings; the '724's title, inventors, assignees and priority date come from PubChem/Google Patents records; Orange Book expiry and Paragraph IV status come from FDA approval letters for ANDAs 090713 and 201533. I could not confirm: the asserted claims against Gavis, Gavis's ANDA number, the substantive settlement terms, Gavis's answer or any counterclaims, or any IPR petition challenging the '724 (the invalidity challenge I can document ran through the district court/Teva appeal, not the PTAB — treat any IPR linkage claim as unverified). Defense counsel of record was Sheila Raftery Wiggins (D.E. 10); I did not verify her firm.

I'll research this case and its related family litigation.

Let me dig into the specific docket and the Gavis disposition.

I'll research this docket and identify plaintiff's counsel of record.

Good initial hits. Let me pull the actual docket/complaint to confirm who signed and appeared.

Let me locate the actual complaint/docket images for 15-1228 to confirm the signature block, plus verify each attorney's firm.

Counsel of Record for Plaintiffs — Helsinn Healthcare S.A. v. Gavis Pharma LLC, No. 3:15-cv-01228 (D.N.J.)

Bottom line: This was a short-lived ANDA/§ 271(e)(2) case on the '724 patent (filed Feb. 13, 2015; terminated by consent judgment and dismissal order, Dkt. 15, signed by Judge Mary L. Cooper on Aug. 25, 2015). The plaintiff side was staffed exactly the way Helsinn staffed all of its Aloxi®/palonosetron cases in this period: Saul Ewing LLP (Newark) as New Jersey counsel of record, with Paul Hastings LLP (New York) as Helsinn's national Hatch-Waxman counsel, and Loeb & Loeb LLP (New York) acting for co-plaintiff Roche Palo Alto LLC in the sister cases.

Attorneys appearing of record on the 15-1228 docket

Lead/behind-the-scenes counsel (named in the related Aloxi® pleadings, not separately appeared here)

In every contemporaneous Helsinn complaint and Rule 11.2/40.1 certification I retrieved (e.g., Helsinn v. Dr. Reddy's, No. 11‑3962; Helsinn v. Hospira, No. 15‑2077; Helsinn v. Actavis), the signature blocks run:

• Joseph M. O'Malley, Jr. — Paul Hastings LLP, New York; de facto lead national counsel for Helsinn in the palonosetron/Aloxi® program. Caution: I did not find a notice of appearance by him on the 15‑1228 docket, so he is best described as lead counsel on the Helsinn account rather than formally "of record" in this docket.
• Bruce M. Wexler, David M. Conca, Gary Ji, Angela C. Ni (and later Isaac S. Ashkenazi, Young J. Park, Dana Weir) — Paul Hastings LLP, New York; "Of Counsel" on the Helsinn pleadings. Ashkenazi is the Paul Hastings name that appears on Helsinn's later Aloxi® suits (e.g., Helsinn v. Gland Pharma, 3:22‑cv‑04635).
• Mark E. Waddell — Loeb & Loeb LLP, 345 Park Avenue, New York, NY; counsel for Roche Palo Alto LLC specifically in the sister actions. I could not retrieve the 15‑1228 complaint signature block, so I cannot confirm whether Loeb & Loeb signed for Roche in this particular complaint; Roche does not appear to have a separate notice of appearance on the docket.
• In-house counsel: none appears on the docket. Helsinn and Roche in-house attorneys are not identified in any filing I retrieved.

Sourcing and stated gaps

• Docket entries and party/attorney listings: UniCourt docket transcription of Helsinn Healthcare S.A. et al v. Gavis Pharma LLC, No. 3:15‑cv‑01228 (D.N.J.) — https://unicourt.com/case/rc-db1-helsinn-healthcare-sa-et-al-v-gavis-pharma-llc-[617687](/patent/617687) (Dkts. 1–15, incl. appearances at Dkts. 6, 7, 9 and consent judgment at Dkt. 15).
• Firm affiliations, office addresses, and national-team composition: signature blocks in Helsinn Healthcare S.A. v. Dr. Reddy's Labs., No. 11‑3962 (D.N.J.) filings (e.g., Dkt. 178, Declaration of Angela C. Ni — https://storage.courtlistener.com/recap/gov.uscourts.njd.[261662](/patent/261662).178.0.pdf); Helsinn complaints reproduced at P-TACTS (e.g., https://ptacts.uspto.gov/ptacts/public-informations/petitions/[1458462](/patent/1458462)/download-documents); and the D.N.J. dismissal letter in Helsinn v. Fresenius Kabi, No. 15‑7378 ("This firm, together with Paul Hastings LLP and Loeb & Loeb LLP, represents plaintiffs…").
• Corroboration of Saul Ewing/Paul Hastings as Helsinn's D.N.J. team: Helsinn v. Hospira, No. 15‑2077, reported at 2016 WL … (D.N.J. Apr. 5, 2016) — "Attorneys: Charles Michael Lizza (Saul Ewing, LLP) for Helsinn Healthcare S.A. and Roche Palo Alto LLC."
• Not verified: (1) the signature block of the actual 15‑1228 complaint (Dkt. 1) — I inferred its structure from parallel complaints rather than reading it; (2) Sarah Ann Sullivan's firm at the time of her Feb. 2015 appearance; (3) whether any sealed filing names additional counsel (nothing in the docket suggests sealing, but the CJO/dismissal papers were not retrieved in full). Sheila Raftery Wiggins appears at Dkt. 10 as defense counsel for Gavis, not plaintiff-side.

I'll research the docket and counsel appearances for this case.

Counsel of Record — Defendant GAVIS Pharma LLC

Helsinn Healthcare S.A. et al. v. Gavis Pharma LLC, No. 3:15-cv-01228-MLC-DEA (D.N.J.) (Cooper, J.; Arpert, M.J.)

Bottom line

Only one attorney appears on the docket as counsel of record for Gavis: Sheila Raftery Wiggins of Duane Morris LLP (New Jersey offices). There is no indication of any pro hac vice admission, no second defense appearance, and no in-house counsel appearance in this docket. The case was extremely short-lived — complaint filed Feb. 13, 2015, waiver of service Mar. 12, 2015, and Consent Judgment and Dismissal Order entered Aug. 25, 2015 (D.I. 15) — so no answer, Rule 26(f) conference, or substantive motion practice ever generated additional appearances.

The attorney of record

Docket support: D.I. 10 — Notice of Appearance by Sheila Raftery Wiggins on behalf of Gavis Pharma LLC (entered May 8, 2015); she also filed D.I. 11 (application for clerk's extension of time to answer) and D.I. 12 (motion for extension), which produced the consent order at D.I. 13 extending Gavis's response date to June 25, 2015.

Unverified / do not rely on without checking PACER

• Frederick R. Ball (Duane Morris LLP, Boston) appeared as "Of Counsel" for Novel Laboratories and Gavis in the parallel Roxane matter (No. 2:15-cv-5618) and was the firm's Boston-based Hatch-Waxman lawyer for that client. It is plausible he was involved behind the scenes here, but I found no appearance, pro hac vice motion, or signature by him on this docket, so he should not be listed as counsel of record for this case.
• No in-house counsel for Gavis (or its then-parent) appears of record. (For context, Gavis Pharmaceuticals LLC was acquired by Amneal in 2016, after this case closed.)
• No sealed appearances or sealed scheduling filings were identified; the docket as indexed is entirely public and consists of ~15 entries.

Sourcing caveat

PACER itself was not directly queried for this response. The appearance information comes from a third-party index of the D.N.J. docket (UniCourt's reproduction of the court's docket sheet, last updated June 6, 2016), cross-checked against Duane Morris-signed filings in related D.N.J. matters retrieved from CourtListener/RECAP and paragraphfour.com. Given the case is closed and the docket is only 15 entries long, the single-appearance picture is likely complete, but the definitive verification is D.I. 10 on PACER (and a check of the D.I. 15 consent judgment's signature block, which would confirm whether any additional defense counsel signed).

Practical note for the case analysis

Because Gavis never answered and the case terminated by consent judgment within roughly six months, there is no defense pleading, invalidity contention, or claim-construction position attributable to Gavis in this docket. Any substantive defense narrative for Gavis must be drawn from the parallel ALOXI® litigations (e.g., Helsinn v. Dr. Reddy's, No. 11-3962/12-2867; Helsinn v. Teva; Roxane v. Novel/Gavis), not from No. 15-1228.